rtmark
LearnBonds.com

Pfizer Inc. (NYSE:PFE) Unveils Noteable Progress in Cancer Research

Pfizer NYSE:PFE
Pfizer Inc.  said that the firm will have its largest presence to date at the 52nd annual meeting of the American Society of Clinical Oncology (ASCO). This will take place in Chicago from June 3-7. It will have more than 40 abstracts spanning a diverse and growing portfolio seeking to tackle many cancers and methods of action. There will be 8 talks. There will also be 5 poster talks. These will span Pfizer’s in-house and joint progress in science. Before that, the firm is set to present at the UBS Global Healthcare Conference on Monday.
Pfizer NYSE:PFE

Pfizer Inc. Rolls Out New Infusion System

Hospira is a Pfizer provider of infusion tech. It declared the launch of the LifeCare PCA® 7.0 Infusion System. As the first patient-controlled analgesia (PCA) infusion pump to offer electronic medical record (EMR) integration (also known as I.V.-EMR interoperability), LifeCare PCA 7.0 is a next-generation infusion system. It allows for device auto-programming. It also streamlines the flow of infusion data. This helps to ensure the safety and efficiency of injecting pain meds.

It is the first ever PCA pump with a built-in bar code reader in order to identify prefilled and pharmacy-filled drug vials. This greatly reduces the chance of drug and concentration errors at the bedside. Medication errors affect 1.5 mn people and cost $21 bn annually. The EMR integration and bar-code technology give health care providers the confidence that the right drug is being given to the patient at the right dose and in the right concentration.

Going All Out Against Cancer

Merck KGaA, which is based in Darmstadt, Germany, and Pfizer said that Avelumab presentations for 7 types of tumors will be featured at the above-mentioned meeting in Chicago, IL. This includes two oral talks. These are from the fast growing JAVELIN clinical development program. They include new study results from a lot of difficult-to-treat cancers, including data from the pivotal Phase II trial of Avelumab being tried as a second-line treatment for metastatic Merkel cell carcinoma (MCC). Other data includes highlights from mesothelioma, adrenocortical carcinoma, non-small cell lung cancer, and urothelial bladder, gastric and ovarian cancers. It will also include new safety data.
‘One of our key highlights for ASCO will be the new Avelumab data in second-line metastatic Merkel cell carcinoma,’ said Luciano Rossetti, executive VP, global head of R&D at the biopharma business of Merck KGaA. The firm operates as EMD Serono in the USA and Canada. ‘As for now there are no approved treatments for this rare and aggressive cancer, these clinically useful data represent a breakthrough for this difficult-to-treat tumor type.’
Since ASCO 2015, joint efforts made by Merck and Pfizer have made a lot of progress. The JAVELIN development program for Avelumab now has 30 ongoing clinical programs and 9 pivotal studies.

Pfizer Inc. also said that its ‘Ibrance’ drug, when used with another ordinarily-used drug, kept advanced breast cancer in check for longer than the standard treatment alone, in a late stage study. This was as per data released on Wednesday.

Ibrance got a fast U.S. authorization in February 2015 based on its ability to delay disease progress in an earlier, smaller Phase II clinical trial. The condition required was that the results be replicated in a larger study in order to gain full approval . The oral drug has a list price of about $10,300 a month. It has fast gained acceptance with oncologists as an improvement over previous treatments. Some 28,000 women in the U.S. have obtained Ibrance since the fast authorization, Pfizer Inc. stated.

All trading carries risk. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Avatar
X

Leading Social Trading Platform with 0% Commission

Leading Social Trading Platform with 0% Commission

Leading Social Trading Platform with 0% Commission

TRADE WITH ETORO

75% of investors lose money when trading CFDs.

Leading Social Trading Platform with 0% Commission
TRADE WITH ETORO

75% of investors lose money when trading CFDs.

HTML Snippets Powered By : XYZScripts.com